Headlines

Money isn’t everything. Let’s talk about what makes life worth living
1 year ago1 year ago
China Set to Announce Major Fiscal Stimulus Amid U.S. Policy Shifts Under Trump
1 year ago1 year ago
LinkedIn SEO: The Ultimate Guide to Maximizing Your Professional Visibility in 2024
1 year ago1 year ago
Trump’s Provocative Rhetoric Fuels Gender Dynamics
1 year ago1 year ago
Meta’s Bullish Report: AI Drives Q3 Growth
1 year ago1 year ago
Bitcoin Could Hit $101,694 By January, Says 10x Research
1 year ago1 year ago
Analysts Ratings: Here Are Top 5 Downgrades For Wednesday
1 year ago1 year ago
10 Proven Ways to Make Money Online in 2024: A Beginner’s Guide
1 year ago1 year ago
Tesla’s Semi Truck Rollout and Charging Infrastructure Challenges
1 year ago
How are AI investments leading to mass layoffs in tech?
1 year ago
Genmo’s Mochi 1: Revolutionizing AI Video Generation with Open-Source Access
1 year ago1 year ago
Tech Industry Jobs: AI’s Impact on Tech Workforce
1 year ago1 year ago

Uncategorized

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

1 year ago01 mins

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming trial results in 2025-2026.

Leave a Reply Cancel reply

Related News

Earnings Scheduled For September 30, 2025

Sumain Faisal5 months ago 0

4 Real Estate Players Recede In Momentum Despite A Fed Rate Cut

Sumain Faisal5 months ago 0

Miami, Dubai Lead Global Real Estate Bubble Risk Surge As Prices Soar Despite Cooling Markets, UBS Warns

Sumain Faisal5 months ago 0

Apple Risks Falling Behind In AI Arms Race, Says Wedbush’s Dan Ives: ‘Biggest Strategic Mistake’ Was Not Buying Netflix

Sumain Faisal5 months ago 0